Investors Face August Deadline in GeneDx Securities Fraud Litigation

The litigation centers on allegations that GeneDx misled shareholders regarding the integration and business viability of its acquisition of Fabric. According to the complaint, the company repeatedly issued statements suggesting the merger would improve financial performance and streamline dry lab processes by combining technological capabilities. The lawsuit claims these representations were false, asserting that executives knew of or recklessly disregarded significant issues within Fabric that threatened the company’s operations.

Investors who acquired shares during the specified period may be eligible for compensation through a contingency fee arrangement, meaning no out-of-pocket costs are required to join the action. While a lawsuit has been filed, no class has been certified yet. Shareholders are not required to serve as lead plaintiff to participate in any future recovery, though they may choose to retain personal counsel or remain absent class members. Interested parties can contact Phillip Kim at the Rosen Law Firm for further case information.